Many political leaders increasingly view regulatory exclusivity as a lucrative handout to pharmaceutical companies. In a new DC Journal op-ed, Professor Kristina M. L. Acri née Lybecker explains why that narrative is mistaken -- and cautions against policies that would weaken exclusivity and discourage the investments that lead to new medicines.

With the Supreme Court set to hear Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., key questions are coming into focus. How might the Court's decision reshape strategies for brand-name and generic manufacturers? And what risks will companies face when marketing “skinny label” products?